Preclinical in vitro and in vivo agent development assays - repurposing itraconazole for topical treatment of basal cell carcinoma in patients with basal cell nevus syndrome.
Ended Awarded Last action
- Contract number
- HHSN26100004
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $20,570
Award facts
- Contract value 100% obligated
- $20,569.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$40,383 | |
| Change Order | -$450,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $510,953 |
Quick answers
Who was awarded contract HHSN26100004?
HHSN26100004 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 20, 2012.
How much is contract HHSN26100004 worth?
The government has obligated $20,570 on HHSN26100004.
Is contract HHSN26100004 an order under another contract?
Yes. HHSN26100004 is a delivery order under HHSN261201200018I, an indefinite delivery contract, on Preclinical Agent Development Assays 2012-2016.
Was contract HHSN26100004 competed?
The extent of competition for HHSN26100004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award